Is biontech (bntx) a good stock to buy?

BioNTech ( BNTX 1.50%), a company that rose to great prominence and a high stock price during the coronavirus pandemic, wasn't much of a star in the past few sessions on the stock market. According to data compiled by S&P Global Market Intelligence, the Germany-based biotech's stock fell by nearly 15% over the course of the week.

Does bntx pay a dividend?

No significant news for BNTX in the past two years. BNTX is not currently paying a regular dividend. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators.

What is bntx benchmark?

Benchmark is MSCI WORLD Select to analyze similar companies using key performance metrics; select up to 4 stocks. BNTX does not have Company Insights BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid.